Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune therapy with COVID-19 convalescent plasma plus standard treatment vs standard treatment alone in severe COVID-19 (phase 2b)
2020-002122-82Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Change in SOFA score from baseline to Day 8. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-002122-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002122-82.